India, Oct. 7 -- For many individuals who deal with issues of being obese or overweight, weight-loss drugs seem like the only possible solution. This is one of the reasons that has led to the ever-evolving growth of the anti-obesity drugs. Among these, the ones that come have injectable versions of GLP-1-based drugs that are most common.

Research conducted by Goldman Sachs on the drug market has revealed that anti-obesity drugs alone are expected to hit $95 billion by 2030. The result reflects how the trend of depending on such drugs influences their demand, their pricing. Asad Haider, head of the healthcare business unit within Goldman Sachs Research, mentions that these also reveal how long patients stay on anti-obesity drugs and how p...